Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2015

View Archived Issues

PROTACs: tagging disease-associated proteins for degradation

C9orf72 knockout insufficient to cause motor neuron diseases in mice

PeptiDream and Teijin agree discovery collaboration

Bone Therapeutics initiates trial of ALLOB for minimally invasive revision spinal surgery

Intrexon and Ziopharm Oncology form exclusive channel collaboration in GvHD

PPOX identified as a new target for colorectal cancer therapy

Aldeyra Therapeutics enrolls first patient in phase IIa trial of NS-2

Novan Therapeutics reports IIb trial data for SB-204 for in acne vulgaris

Macrophage Therapeutics produces first two immunoconstructs

BLU-554 receives FDA orphan drug designation for hepatocellular carcinoma

Polyphor/Roche macrocyclic peptide to combat multidrug-resistant bacterial infections

PTC Therapeutics submits variation for new indication in Europe for Translarna

BiondVax begins phase IIb trial of universal flu vaccine in Europe

SEQ-9, a novel macrolide for the treatment of tuberculosis

Zosano discontinues daily ZP-PTH and resumes development of weekly formulation

Novel 2-pyridone antibacterials to treat Gram-negative bacterial infections

AMO Pharma raises funds to advance clinical-stage candidates and expand pipeline

reMYND develops new compounds for protein-misfolding disorders

iTeos Therapeutics describes TDO2 inhibitors

Tyme submits phase II IND application for SM-88

Incretin effect identified as a predictor of prediabetes in women with previous GDM

Trillium advances TTI-621 towards phase I trials

Merck & Co. presents SYK inhibitors

FDA awards QIDP designation to Ixogel for prevention of Lyme disease

Ignyta initiates phase II trial of entrectinib

BioMarin to acquire global rights to Kuvan and pegvaliase from Merck Serono

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...